Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia.
Acute myeloid leukemia
Cell therapy
Donor lymphocyte infusion
Haploidentical stem cell Transplantation
Journal
Annals of hematology
ISSN: 1432-0584
Titre abrégé: Ann Hematol
Pays: Germany
ID NLM: 9107334
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
26
02
2021
accepted:
17
11
2021
pubmed:
7
1
2022
medline:
11
2
2022
entrez:
6
1
2022
Statut:
ppublish
Résumé
Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. We retrospectively analyzed the outcomes after haploidentical DLI for 84 patients with AML using a nationwide database and additional questionnaires. The median number of DLI cycles and infused CD3
Identifiants
pubmed: 34988692
doi: 10.1007/s00277-021-04731-5
pii: 10.1007/s00277-021-04731-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
643-653Subventions
Organisme : Japan Agency for Medical Research and Development
ID : 18ek0510023h0002
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Schmid C, Labopin M, Nagler A et al (2007) Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute leukemia Working Party. J Clin Oncol 25:4938–4945
doi: 10.1200/JCO.2007.11.6053
Takami A, Yano S, Yokoyama H et al (2014) Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the adult acute myeloid leukemia working group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 20:1785–1790
doi: 10.1016/j.bbmt.2014.07.010
Miyamoto T, Fukuda T, Nakashima M et al (2017) Donor lymphocyte infusion for relapsed hematological malignancies after unrelated allogeneic bone marrow transplantation facilitated by the Japan Marrow Donor Program. Biol Blood Marrow Transplant 23:938–944
doi: 10.1016/j.bbmt.2017.02.012
Hofmann S, Schmitt M, Götz M et al (2019) Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. Int J Cancer 144:1135–1146
doi: 10.1002/ijc.31753
Liu L, Chang YJ, Xu LP et al (2018) Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after allo-HSCT. Biol Blood Marrow Transplant 24:1350–1359
doi: 10.1016/j.bbmt.2018.03.030
Chalandon Y, Passweg JR, Schmid C et al (2010) Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the chronic leukemia working party of the EBMT. Bone Marrow Transplant 45:558–564
doi: 10.1038/bmt.2009.177
Luznik L, O’Donnell PV, Symons HJ et al (2008) HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 14:641–650
doi: 10.1016/j.bbmt.2008.03.005
Sugita J (2019) HLA-haploidentical stem cell transplantation using posttransplant cyclophosphamide. Int J Hematol 110:30–38
doi: 10.1007/s12185-019-02660-8
Baron F, Mohty M, Blaise D et al (2017) Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Haematologica 102:224–234
doi: 10.3324/haematol.2016.148510
Ikegame K, Yoshida T, Yoshihara S et al (2015) Unmanipulated haploidentical reduced-intensity stem cell transplantation using fludarabine, busulfan, low-dose antithymocyte globulin, and steroids for patients in non-complete remission or at high risk of relapse: A prospective multicenter Phase I/II study in Japan. Biol Blood Marrow Transplant 21:1495–1505
doi: 10.1016/j.bbmt.2015.04.012
Zeidan AM, Forde PM, Symons H et al (2014) HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:314–318
doi: 10.1016/j.bbmt.2013.11.020
Ghiso A, Raiola AM, Gualandi F et al (2015) DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant 50:56–61
doi: 10.1038/bmt.2014.217
Goldsmith SR, Slade M, DiPersio JF et al (2017) Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplant 52:1623–1628
doi: 10.1038/bmt.2017.193
Huang XJ, Liu DH, Liu KY et al (2007) Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 92:414–417
doi: 10.3324/haematol.10570
Yan CH, Liu DH, Xu LP et al (2012) Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant 26:868–876
doi: 10.1111/j.1399-0012.2012.01618.x
Dholaria B, Savani BN, Labopin M et al (2020) Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica 105:47–58
doi: 10.3324/haematol.2019.219790
Yan CH, Liu QF, Wu DP et al (2017) Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia. Biol Blood Marrow Transplant 23:1311–1319
doi: 10.1016/j.bbmt.2017.04.028
Gao XN, Lin J, Wang LJ et al (2019) Comparison of the safety and efficacy of prophylactic donor lymphocyte infusion after haploidentical versus matched-sibling PBSCT in very high-risk acute myeloid leukemia. Ann Hematol 98:1267–1277
doi: 10.1007/s00277-019-03636-8
Yan CH, Xu LP, Liu DH et al (2015) Low-dose methotrexate may preserve a stronger antileukemic effect than that of cyclosporine after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. Clin Transplant 29:594–605
doi: 10.1111/ctr.12561
Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3–10
doi: 10.1007/s12185-015-1894-x
Kanda J (2016) Scripts for TRUMP data analyses. part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol 103:11–19
doi: 10.1007/s12185-015-1907-9
Yanada M, Mori J, Aoki J et al (2018) Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma 59:601–609
doi: 10.1080/10428194.2017.1357173
nccn.org [internet]. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 2. 2021. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx . Accessed 27 Feb 2021
Przepiorka D, Weisdorf D, Martin P, et al. (1995) 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15:825–828
Sullivan KM, Agura E, Anasetti C et al (1991) Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28:250–259
pubmed: 1887253
Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458
doi: 10.1038/bmt.2012.244
Battipaglia G, Labopin M, Kröger N et al (2019) Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation. Blood 134:892–899
doi: 10.1182/blood.2019000487
Ruggeri A, Sun Y, Labopin M et al (2017) Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant. Haematologica 102:401–410
doi: 10.3324/haematol.2016.151779
Eefting M, von dem Borne PA, de Wreede LC et al (2014) Intentional donor lymphocyte-induced limited acute graft-versus-host disease is essential for long-term survival of relapsed acute myeloid leukemia after allogeneic stem cell transplantation. Haematologica 99:751–758
doi: 10.3324/haematol.2013.089565
Guillaume T, Malard F, Magro L et al (2019) Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54:1815–1826
doi: 10.1038/s41409-019-0536-y
Chen YB, Li S, Lane AA et al (2014) Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant 20:2042–2048
doi: 10.1016/j.bbmt.2014.09.007
Sandmaier BM, Khaled S, Oran B et al (2018) Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant. Am J Hematol 93:222–231
doi: 10.1002/ajh.24959